Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging.
| Title: | Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging. |
|---|---|
| Authors: | Teleanu DM; Emergency University Hospital, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania. daniel.teleanu@umfcd.ro.; Chircov C; Faculty of Engineering in Foreign Languages, Politehnica University of Bucharest, 060042 Bucharest, Romania. cristina.chircov@yahoo.com.; Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania. cristina.chircov@yahoo.com.; Grumezescu AM; Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania. grumezescu@yahoo.com.; ICUB - Research Institute of University of Bucharest, University of Bucharest, 36-46 M. Kogalniceanu Blvd., Bucharest 050107, Romania. grumezescu@yahoo.com.; Volceanov A; Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania. avolceanov@yahoo.co.uk.; Teleanu RI; 'Victor Gomoiu' Clinical Children's Hospital, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania. raluca.teleanu@umfcd.ro. |
| Source: | Nanomaterials (Basel, Switzerland) [Nanomaterials (Basel)] 2019 Apr 03; Vol. 9 (4). Date of Electronic Publication: 2019 Apr 03. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101610216 Publication Model: Electronic Cited Medium: Print ISSN: 2079-4991 (Print) Linking ISSN: 20794991 NLM ISO Abbreviation: Nanomaterials (Basel) Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI AG, [2011]- |
| Abstract: | Neuroimaging is a highly important field of neuroscience, with direct implications for the early diagnosis and progression monitoring of brain-associated diseases. Neuroimaging techniques are categorized into structural, functional and molecular neuroimaging, each possessing advantages and disadvantages in terms of resolution, invasiveness, toxicity of contrast agents and costs. Nanotechnology-based approaches for neuroimaging mostly involve the development of nanocarriers for incorporating contrast agents or the use of nanomaterials as imaging agents. Inorganic and organic nanoparticles, liposomes, micelles, nanobodies and quantum dots are some of the most studied candidates for the delivery of contrast agents for neuroimaging. This paper focuses on describing the conventional modalities used for imaging and the applications of nanotechnology for developing novel strategies for neuroimaging. The aim is to highlight the roles of nanocarriers for enhancing and/or overcome the limitations associated with the most commonly utilized neuroimaging modalities. For future directions, several techniques that could benefit from the increased contrast induced by using imaging probes are presented. |
| References: | Front Neuroinform. 2016 Apr 25;10:15. (PMID: 27199729); J Biomed Nanotechnol. 2016 Feb;12(2):347-56. (PMID: 27305768); Colloids Surf B Biointerfaces. 2016 Nov 1;147:129-141. (PMID: 27497076); Sci Rep. 2016 Sep 21;6:33791. (PMID: 27650487); Br J Radiol. 2016 Nov;89(1067):20150806. (PMID: 27653465); Nanoscale. 2017 Dec 21;10(1):184-194. (PMID: 29210401); J Control Release. 2016 Dec 10;243:1-10. (PMID: 27671875); Int Rev Neurobiol. 2018;142:335-380. (PMID: 30409258); Neurosci Biobehav Rev. 2018 Jul;90:104-114. (PMID: 29656030); Handb Clin Neurol. 2016;135:61-92. (PMID: 27432660); J Transl Med. 2017 Jan 23;15(1):18. (PMID: 28114956); Epilepsy Behav. 2018 Aug;85:115-119. (PMID: 29940374); Int J Nanomedicine. 2017 Sep 26;12:7075-7088. (PMID: 29026302); Curr Alzheimer Res. 2016;13(5):487-97. (PMID: 26567731); Brachytherapy. 2018 Sep - Oct;17(5):816-824. (PMID: 29880449); Handb Clin Neurol. 2016;135:229-240. (PMID: 27432668); Parkinsons Dis. 2016;2016:3217960. (PMID: 27190672); Prog Brain Res. 2016;225:123-52. (PMID: 27130414); Neuroimage. 2018 Nov 1;181:692-717. (PMID: 29753843); IEEE Trans Ultrason Ferroelectr Freq Control. 2016 Dec;63(12):2001-2007. (PMID: 27576247); Int J Nanomedicine. 2018 Sep 20;13:5561-5576. (PMID: 30271147); Stroke. 2016 Apr;47(4):1153-8. (PMID: 26965849); Nat Neurosci. 2018 Apr;21(4):474-483. (PMID: 29507407); Curr Opin Biomed Eng. 2017 Dec;4:78-86. (PMID: 29457144); Sci Transl Med. 2017 Oct 11;9(411):. (PMID: 29021168); Handb Clin Neurol. 2016;135:209-227. (PMID: 27432667); Sci Rep. 2015 Oct 06;5:14759. (PMID: 26440059); ACS Chem Neurosci. 2018 Mar 21;9(3):395-397. (PMID: 29431424); J Am Coll Radiol. 2010 Aug;7(8):650-2. (PMID: 20678736); BJA Educ. 2018 Oct;18(10):300-309. (PMID: 33456794); ACS Chem Biol. 2016 Oct 21;11(10):2812-2819. (PMID: 27513597); J Mater Chem B. 2017 Sep 21;5(35):7216-7237. (PMID: 32264173); Methods Enzymol. 2018;603:257-277. (PMID: 29673530); Exp Neurobiol. 2016 Dec;25(6):277-295. (PMID: 28035179); Biomaterials. 2016 Jan;77:291-306. (PMID: 26615367); Front Hum Neurosci. 2017 May 17;11:258. (PMID: 28567011); Oncotarget. 2016 Jun 21;7(25):38693-38706. (PMID: 27231848); Clin EEG Neurosci. 2019 Jan;50(1):20-33. (PMID: 29925268); Adv Drug Deliv Rev. 2017 Apr;113:157-176. (PMID: 27521055); Artif Intell Med. 2016 Oct;73:45-69. (PMID: 27926381); Sci Rep. 2017 Sep 21;7(1):12045. (PMID: 28935923); Adv Funct Mater. 2017 Oct 19;27(39):. (PMID: 30853878); Nanomedicine. 2018 Oct;14(7):2341-2350. (PMID: 29079529); Contrast Media Mol Imaging. 2018 Jun 25;2018:3476476. (PMID: 30079001); Acta Biomater. 2017 Jan 1;47:182-192. (PMID: 27721007); Biomed Imaging Interv J. 2006 Apr;2(2):e8. (PMID: 21614236); Cancer Chemother Pharmacol. 2016 Feb;77(2):269-80. (PMID: 26666650); Genome Med. 2017 Nov 27;9(1):102. (PMID: 29179742); Annu Rev Anal Chem (Palo Alto Calif). 2016 Jun 12;9(1):95-115. (PMID: 27049630); Mol Cancer Ther. 2017 Sep;16(9):1909-1921. (PMID: 28659432); Nanomedicine. 2017 Jan;13(1):83-93. (PMID: 27682740); Nanotheranostics. 2018 Feb 15;2(2):168-183. (PMID: 29577020); J Neural Eng. 2015 Oct;12(5):056018. (PMID: 26394650); Phys Med Biol. 2013 Jan 7;58(1):R1-35. (PMID: 23220766); Ageing Res Rev. 2016 Sep;30:1-3. (PMID: 26976625); Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1350-5. (PMID: 25605916); Pharmaceutics. 2011 Apr 04;3(2):141-70. (PMID: 24310493); Front Hum Neurosci. 2018 Jan 08;11:641. (PMID: 29358912); Neuropsychol Rev. 2015 Sep;25(3):289-313. (PMID: 26248581); 3 Biotech. 2018 Jun;8(6):279. (PMID: 29881657); Handb Clin Neurol. 2016;135:241-250. (PMID: 27432669); J Pain Res. 2016 Sep 08;9:613-24. (PMID: 27660488); Biochim Biophys Acta Gen Subj. 2017 Jun;1861(6):1515-1520. (PMID: 28017683); EBioMedicine. 2016 Jun;8:40-48. (PMID: 27428417); Prim Care. 2018 Sep;45(3):505-518. (PMID: 30115337); Drug Discov Today. 2016 Jul;21(7):1076-113. (PMID: 27080147); Handb Clin Neurol. 2016;135:117-135. (PMID: 27432662); Comput Math Methods Med. 2015;2015:530580. (PMID: 26576198); Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2586-2591. (PMID: 28223513); Rep Pract Oncol Radiother. 2019 Jan-Feb;24(1):12-19. (PMID: 30337843); Int J Mol Sci. 2017 Feb 01;18(2):. (PMID: 28157157); J Control Release. 2017 May 10;253:165-171. (PMID: 28322975); J Transl Med. 2015 Sep 23;13:313. (PMID: 26394751); AAPS PharmSciTech. 2017 Jul;18(5):1564-1571. (PMID: 27604884); Nat Methods. 2016 Jul 28;13(8):627-38. (PMID: 27467726); Nanomedicine (Lond). 2016 Apr;11(7):833-49. (PMID: 26980585); Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):691-707. (PMID: 25683687); Nanomedicine. 2015 Aug;11(6):1345-54. (PMID: 25888277); Int J Nanomedicine. 2016 Oct 18;11:5381-5414. (PMID: 27799765); Theranostics. 2018 Feb 2;8(5):1195-1212. (PMID: 29507614); J Clin Neurosci. 2019 Jan;59:284-290. (PMID: 30391310); Front Neurol. 2017 Aug 24;8:407. (PMID: 28883806); Front Neurol. 2018 May 14;9:328. (PMID: 29867737); Curr Opin Neurobiol. 2018 Jun;50:128-135. (PMID: 29477979); Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):14133-14138. (PMID: 27911765); Am J Med. 2018 Aug;131(8):874-882. (PMID: 29371158); Handb Clin Neurol. 2017;145:301-307. (PMID: 28987178); ACS Appl Mater Interfaces. 2014 Nov 26;6(22):19850-7. (PMID: 25335117); Handb Clin Neurol. 2012;106:89-95. (PMID: 22608617); Prog Neuropsychopharmacol Biol Psychiatry. 2018 Dec 20;87(Pt B):224-233. (PMID: 28627447); Neuroimage. 2017 Apr 1;149:267-274. (PMID: 28167348); Nanomedicine (Lond). 2018 Sep;13(18):2341-2371. (PMID: 30088440); Chem Soc Rev. 2018 Nov 26;47(23):8572-8610. (PMID: 30177983); Radiology. 2017 Sep;284(3):616-629. (PMID: 28825888); Crit Rev Biomed Eng. 2016;44(1-2):123-52. (PMID: 27652455); Neurophotonics. 2016 Jul;3(3):031402. (PMID: 26958576); Pharmaceutics. 2018 Dec 11;10(4):. (PMID: 30544966); J Neurosurg. 2018 May 25;130(4):1180-1192. (PMID: 29799342); Front Neurosci. 2019 Feb 01;13:12. (PMID: 30778281); Sci Rep. 2017 Jun 15;7(1):3587. (PMID: 28620162); Adv Colloid Interface Sci. 2017 Nov;249:192-212. (PMID: 28499604); Nature. 2016 Aug 11;536(7615):171-178. (PMID: 27437579); Int J Nanomedicine. 2018 Aug 10;13:4607-4625. (PMID: 30127609); Am J Med. 2018 Apr;131(4):346-356. (PMID: 29191488); Korean J Anesthesiol. 2018 Feb;71(1):12-21. (PMID: 29441170); Sci Rep. 2018 Jul 30;8(1):11412. (PMID: 30061729) |
| Contributed Indexing: | Keywords: contrast agents; imaging; nanotechnology; neuroimaging; neuroscience |
| Entry Date(s): | Date Created: 20190417 Latest Revision: 20231011 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6523665 |
| DOI: | 10.3390/nano9040542 |
| PMID: | 30987211 |
| Database: | MEDLINE |
Journal Article; Review